RNATICS develops nucleic acid therapies targeting disease-causing RNAs in tissue resident macrophages via inhalation. The primary target are inflammatory lung diseases with fibrotic lesions induced by viral infections or volatile toxic substances. For the lead candidate RCS-21, an antisense oligonucleotide against miR-21 coupled to a macrophage-targeting moiety, IND-enabling work is ongoing, and we aim to begin first-in-human clinical trials next year.